Immediate Call for Applications
The Vall d´Hebron Institute of Oncology´s (VHIO) recently established Radiomics Group, headed by Raquel Perez-Lopez (MD, PhD), is currently seeking to appoint an MR Research Physicist/Engineer.
This post is a great opportunity to be involved in a broad range of cutting-edge imaging research within the translational research environment of the Vall d’Hebron Institute of Oncology (VHIO), Barcelona (Spain). VHIO is a leading Comprehensive Cancer Centre dedicated to translational cancer research and one of the world-leading drug-development centres for cancer care.
The Radiomics Group at VHIO is focused on medical image processing and the extraction of imaging biomarkers for precision medicine towards improving cancer patients’ care. The candidate will be involved in several research projects such as 1) defining radiomics signatures of response to targeted-therapies and immunotherapy and 2) evaluating differential responses to targeted therapies towards the study of tumour evolution and mechanism of resistance, among others.
This role also involves working in close collaboration with the medical imaging groups at the Computer Vision Centre (CVC) in Barcelona (www.cvc.uab.es) and, particularly, with the Interactive and Augmented Modelling Group (www.iam.cvc.uab.es). The CVC comprises mathematicians and computer science engineers focused on cutting-edge imaging research with medical applications.
The successful candidate will assist in the development, implementation and analysis of functional and quantitative MR studies. This will include the design of scanner protocols, optimization of MR techniques and assisting with the analysis and interpretation of imaging data.
As this new group expands, the candidate will progressively acquire a supervision role over predoctoral students and other junior investigators.
The Radiomics Group at VHIO is committed to the continue training of their scientists and a personal training and development plan will be agreed with the candidate.
An organized and motivated, team-oriented individual with previous experience in MR imaging and medical translational research. The ideal candidate should have previous experience in functional MR protocol implementation, optimization and analysis.
Being familiar with computer, problem solving and analytical skills will be positively considered.
The post-holder will be encouraged to initiate and lead research projects according to his/her interests in line with the group research strategy.
The candidate is expected to be able to communicate in English, even if it is not his/her first language. The candidate will progressively be involved in preparing grant proposals and scientific manuscripts.
The ideal candidate should be familiar with:
- Background in medical imaging research and imaging biomarkers development.
- MR protocol implementation and optimization.
- Doctoral degree or equivalent qualification in physics or engineering.
- Computer, problem solving and analytical skills.
Potential candidates should submit a curriculum vitae and letter of intent via email addressed to Raquel Perez-Lopez: email@example.com
Review of applications will commence immediately.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), created by José Baselga in 2007, has established itself as a comprehensive cancer centre of proven excellence internationally. It is thanks to Josep Tabernero’s directorship and VHIO´s optimal organisational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO´s pioneering model and programmes, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumour types.